Health Investment Returns: Harnessing Health as...

By João L. Carapinha

November 18, 2025

Health as a Strategic Economic Imperative A country's enduring strength stems not solely from military or industrial resources but from the vitality and productivity of its populace. A recen...
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
Weight Loss: Advances in Hormone-Based Obesity Treatments
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for Ig...
Tukysa Breast Cancer Therapy Boosts Progression-Free Survival in Advanced Cases
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications
Transforming Healthcare with the Gene Therapy Access Model
PhRMA’s Patient Access Investment: $500 Billion Commitment to Domestic ...
The Market Dynamics of Track One Patent Strategy in Pharmaceuticals